Navigation Links
SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite
Date:8/5/2009

MUMBAI, India, Aug. 5 /PRNewswire/ -- SIRO Clinpharm, a global, full service Contract Research Organization (CRO) founded in India, today announced the successful completion of the implementation phase of the Oracle Life Science Application Suite (OLSAS) by going live with Oracle Siebel Clinical Trial Management System and Oracle Adverse Events Reporting System.

"We are excited to have the rollout of the entire OLSAS as per our plan for the India operations," said Dr. Ajit Nair, President, India Operations, SIRO Clinpharm. "This will help us manage critical tasks in clinical operations and drug safety in an efficient and globally compliant manner, thus providing our clients the best of technology support to run trials more efficiently."

After this implementation, SIRO gains complete operational functionality of the Oracle suite. SIRO, in April, had gone live with the industry standard Oracle Clinical and Oracle RDC, integrated with TMS for its Clinical Data Management Services.

The OLSAS product portfolio for SIRO is comprised of Siebel Clinical Trial Management System 8.0 (CTMS), Adverse Events Reporting System 4.6 (AERS), Oracle Clinical 4.5.3 (OC), Remote Data Capture 4.5.3 (RDC) and Thesaurus Management System 4.6 (TMS).

SIRO plans to roll out the OLSAS to its European operations soon to have the system working in all geographies in which the company has operations.

About SIRO

SIRO Clinpharm Private Limited (SIRO) is among one of the leading global Clinical Research Organizations (CROs), offering full scope services, conducting clinical trials in the pharmaceutical, biotechnology and medical devices sectors in compliance with international standards. SIRO is one of the first CROs founded in India, which caters to the needs of pharmaceutical companies across the world. The company has offices in India, USA, Israel and in Germany, Romania, Estonia and Greece. SIRO has recently opened offices in Czech Republic & Spain.


'/>"/>
SOURCE SIRO Clinpharm
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
2. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
3. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
4. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
5. Potentia Pharmaceuticals POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
6. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
7. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
8. Major Restless Legs Study Completes Enrollment With Support From MediciGlobal
9. QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
10. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
11. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Fla. , Dec. 9, 2016  Harmar Mobility, LLC announced ... and a member of the Board of Directors. Photo ... ... Mr. Dawson,s ... development of organizations across a variety of industries. He brings to ...
(Date:12/9/2016)... -- Research and Markets has announced the addition of ... offering. ... global travel vaccines market to grow at a CAGR of 6.83% ... scenario and the growth prospects of the global travel vaccines market ... revenue generated from the sales of various vaccines administered to actively ...
(Date:12/8/2016)... -- IRIDEX Corporation (NASDAQ: IRIX ) today announced ... stock, $0.01 par value (the "Offering" with such shares being ... terms of the Offering will depend on market and other ... no assurance as to whether or when the Offering may ... proceeds it will receive from this offering for working capital ...
Breaking Medicine Technology:
(Date:12/9/2016)... PA (PRWEB) , ... December 09, 2016 , ... "I ... Fla. "I used this old family recipe, which is meant to relieve gout and ... it gave me a 12-hour energy boost every time. It relieved what VA doctors ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy ... in New York, NY, on December 3rd, to benefit Holy Name Medical Center's ... annual event, which raised over $1 million - the largest event in the ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital ... and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation ... a few hospitals and facilities have earned this distinction. This is the second ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
Breaking Medicine News(10 mins):